ADC Therapeutics Grants Stock Options to New Hire

Lausanne-based ADC Therapeutics has issued a stock option grant covering 17,000 common shares to a new employee. The move serves as a material inducement for the hire, following approval from the company’s Board of Directors under the NYSE’s Listed Company Manual Rule 303A.08.

Yesterday, 23:21· Corp and Tech· 646 reads

The options grant, finalized on July 1, 2026, is structured to vest over a four-year period. One-quarter of the shares will become exercisable on the first anniversary of the grant date, with the remainder vesting in monthly increments of 1/48th thereafter. This schedule remains contingent upon the recipient’s continued employment with the firm.

ADC Therapeutics, a commercial-stage leader in antibody drug conjugates, utilized its Inducement Plan to finalize the award. The company maintains operations in both Switzerland and New Jersey, focusing on the development of its flagship therapy, ZYNLONTA, which is currently used to treat relapsed or refractory diffuse large B-cell lymphoma.

ADC Therapeutics Grants Stock Options to New Hire

Comments (0)